In the last 20 years, the consumption of prescription stimulants increased from 5 million to 45 million.
Prescription drug abuse is the nation’s fastest growing drug problem. More people in the U.S. died last year of drug overdoses than from car accidents, making prescription drug abuse the third leading cause of accidental death. In the U.S., one person dies every 19 minutes from a drug overdose, and overdoses involving prescription painkillers now kill more Americans than those involving heroin and cocaine combined. This epidemic has been particularly widespread on college campuses. Between 1993 and 2005, the proportion of college students using prescription drugs went up dramatically: use of opioids such as Vicodin, Oxycontin, and Percocet increased by 343 percent, and use of stimulants like Ritalin or Adderall increased by 93 percent.
Expanding Access to Naloxone
Learn about the Adapt Pharma/Clinton Health Matters Initiative One-time Experience Donation of NARCAN® Nasal Spray.


CHMI seeks to cut prescription drug abuse deaths in half over the next five years – saving approximately 10,000 lives – through strategic partnerships that raise consumer and public awareness, advance business practice change, and mobilize communities.

Naloxone Purchasing Agreements

CHMI has formed national partnerships with two privately held pharmaceutical companies, kaléo and Adapt Pharma, to provide a predictably affordable supply of naloxone to community groups, public safety organizations, and schools and universities, creating a window of opportunity for the naloxone distribution field to scale over the next five years. These partnerships help place this potentially life-saving medicine in the hands of those who can intervene quickly during an opioid overdose emergency. The injectable form of naloxone HCl was first approved by FDA in 1971 and has been the standard of care for the treatment of opioid overdose in the hospital and by emergency medical services for over 40 years.

Johns Hopkins Working Group

In 2014, CHMI engaged Johns Hopkins University as a key research and content partner and, together, the Clinton Foundation and the Johns Hopkins Bloomberg School of Public Health hosted a working meeting and public forum with the goal of taking a public health approach to the prescription drug misuse and abuse epidemic and using evidence to inform policy and practical action.

Northeast Florida: Model Community of Practice

CHMI is partnering with Drug Free Duval to create a replicable and scalable model of intervention at the community level. Together, CHMI and Drug Free Duval will harness the collective resources of local organizations impacted by the epidemic to create an actionable blueprint on how to provide comprehensive and multi-sectoral prevention, treatment, and recovery services for the residents of the Jacksonville, Florida, metropolitan area.

In addition to the immediate and crucial impact of reducing deaths, CHMI aims to integrate naloxone access and implementation into a comprehensive prevention, intervention, treatment, and recovery model that is scalable and replicable across a diverse range of communities and populations. Currently, CHMI is working with partners and stakeholders from the opioid misuse and abuse prevention space to identify a new generation of communities primed not only for increased naloxone access, but a community-based model which incorporates a broad range of prevention and treatment goals.